Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro
Received: 22 February 2017
Accepted: 2 January 2018
First Online: 22 January 2018
Ethics approval and consent to participate
: All questionnaires and materials were processed anonymously.The study was approved by the Ethics Committee of the institutions involved: IRCCS San Raffaele Pisana (Reference Number 02/15) and ASL RM C (Reference Number 24164). The study was conducted in accordance with the International Conference on Harmonization of Good Clinical Practices guidelines and with the ethical principles of the Declaration of Helsinki. The study was registered to ClinicalTrials.govID (NCT03004508) [CitationRef removed]. IDN 5933 (also named Ginkgoselect®Plus) is a registered trademark of Indena S.p.A., Italy.Written informed consent was obtained from all patients.
: Not applicable.
: The authors have declared the following competing interests: The institutions of SB, GP, PL, IP, and GP have received research grant support from Indena SpA. SB received fees for consulting services from Indena SpA. All the other authors have declared no conflict of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.